The p38 MAPK family consists of highly conserved proline-directed serine-threonine protein kinases that are activated in response to a number many growth factors, cytokines, and chemotactic substances, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), PDGF, TNF, interleukins, lipopolysaccharide (LPS) and formyl-methionyl-leucyl-phenylalanine (fMLP).It is well known that p38 plays a role in cell differentiation, cardiomyocyte hypertrophy, apoptosis, and inflammation.
The four proteins that make up the p38 MAPK family are p38 (encoded by the gene Mapk14), p38 (Mapk11), p38 (Mapk12), and p38 (Mapk13). Their coding genes appear to be differentially expressed and have a distinct tissue distribution, with Mapk14 being the most highly expressed. MKK6, MKK3, and MKK4 are three MAP2Ks that p38 MAPKs are a substrate for. Depending on the stimulus and the cell type, each of these MAP2Ks plays a different role in the activation of p38 MAPKs. ASK1, DLK1, TAK1, TAO1, TAO2, TPL2, MLK3, MEKK3, MEKK4, and ZAK1 are the MAP3Ks that activate p38 MAPKs.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V74114 | Macranthoin G (Methyl 3,5-dicaffeoyl quinic acid) | 159934-13-1 | Macranthoin G is an inhibitor (blocker/antagonist) of p38 MAPK. |
|
V74104 | MBP MAPK Substrate | 138028-00-9 | MBP MAPK Substrate can be used as an exogenous substrate for MAPK. |
|
V9029 | Metformin | 657-24-9 | Metformin (La-6023; SMP-862; ADX-155; EFB-0027; EX404; La6023; SMP862; Fortamet) is an approved hypoglycemic drug for the treatment of type 2 diabetes (non-insulin-dependent diabetes mellitus). |
|
V74116 | Mitogen-activated protein kinase 1 (MAPK1) | 137632-08-7 | Mitogen-activated protein kinase 1 (MAPK1) can activate the downstream p38/NF-κB pathway. |
|
V69827 | MK2-IN-5 (Hsp25 kinase inhibitor; Mk2 pseudosubstrate) | 474713-20-7 | MK2-IN-5 is a pseudosubstrate of Mk2 (Ki= 8 μM). |
|
V51569 | MKK7-COV-9 | 2283355-59-7 | covalent inhibitor of MKK7 |
|
V23174 | Muramyl Dipeptide | 53678-77-6 | Muramyl Dipeptide(MDP) is a novel and potent NOD2 agonist. |
|
V74123 | Natsudaidain | 35154-55-3 | Natsudaidain is a polymethoxyflavonoid. |
|
V0482 | Neflamapimod (VX745, VRT031745; VD31745) | 209410-46-8 | Neflamapimod (formerly also known as VX-745, VRT-031745 and VD-31745) is a novel, highly potent and selective inhibitor of p38α MAPK with potential anti-inflammatory activity (e.g. anti-arthritis). |
|
V51556 | OVA-E1 peptide | 153316-01-9 | antagonist variant of SIINFEKL [OVA (257-264) |
|
V51557 | OVA-E1 peptide TFA | 1262750-80-0 | antagonist variant of SIINFEKL [OVA (257-264) |
|
V74109 | p38 Kinase inhibitor 4 | 13142-47-7 | p38 Kinase inhibitor 4 (compound 135) is a potent p38 inhibitor. |
|
V74118 | p38 Kinase inhibitor 5 | 2929285-29-8 | p38 Kinase inhibitor 5 (AA6) is a potent p38 kinase inhibitor (antagonist) with IC50 of 403.57 nM. |
|
V74124 | p38 MAP Kinase Inhibitor VI | 421578-46-3 | p38 MAP Kinase Inhibitor VI (compound c32) is a p38 MAPK inhibitor (antagonist) with an inhibition rate of 24%. |
|
V51698 | p38 MAP modulator | 773104-07-7 | modulator of p38 Mitogen-Activated Protein (MAP) kinase |
|
V74107 | p38 MAPK-IN-4 | 219138-24-6 | p38 MAPK-IN-4 (compound 6) is a p38 MAPK inhibitor, 50 at 35 nM. |
|
V74127 | p38α inhibitor 2 | 1095003-80-7 | p38α inhibitor 2 is a highly efficient and selective p38α MAPK inhibitor (antagonist) with pIC50 of 9.6. |
|
V74126 | p38α inhibitor 4 | 1262406-08-5 | p38α inhibitor 4 (compound 10) is a selective allosteric p38α inhibitor (antagonist) with IC50 of 1.2 μM. |
|
V2663 | Pamapimod | 449811-01-2 | Pamapimod (formerly known as R-1503; Ro-4402257) is a novel and selective inhibitor of p38 mitogen-activated protein kinase (MAPK) with immunomodulatory and anti-inflammatory effects. |
|
V3010 | PD 169316 | 152121-53-4 | PD 169316 is a novel potent, cell-permeable and specific/selective inhibitor of p38 MAPK kinase with IC50 value of 89 nM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
